Description:
Over the past several years, many immuno-oncology modalities have emerged. These modalities, which include checkpoint inhibition, adoptive T-cell therapy (ACT), and cancer vaccines, are often designed to evade immune responses. This is a rapidly growing therapeutic field that embraces the concept of modulating the immune system to recognize tumor cells and target them for destruction. Our Next Gen Immuno-Oncology Congress from past 2 years had gathered the professionals across the globe to deliver such latest developments.
Having completed two extremely successful editions, MarketsandMarkets’ is coming up with “3rd Annual Next-Gen Immuno-Oncology Congress” gathering the academicians, researchers and scientists from research institutes pharmaceutical, biopharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Immune Checkpoint Inhibitors and Adoptive Cellular Therapy.